Metastatic Breast Cancer | Tumor

CURE’s metastatic breast cancer page features the latest cancer news and updates on metastatic breast cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in metastatic breast cancer.

The Role of Circulating Tumor DNA in Breast Cancer Monitoring

March 18th 2025, 1:00pm

Video

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.

Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment

March 15th 2025, 6:00pm

Article

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.

First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer

March 12th 2025, 4:00pm

Article

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.

Vepdegestrant May Reduce Disease Progression in Breast Cancer Subset

March 11th 2025, 4:14pm

Article

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.

Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer

March 1st 2025, 3:00pm

Article

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer

February 27th 2025, 2:00pm

Article

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.

What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar

February 26th 2025, 4:24pm

Video

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

February 19th 2025, 8:00pm

Article

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.

Are We at Risk of Losing Our Breast Cancer Community?

February 14th 2025, 6:00pm

Article

I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.

An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer

February 12th 2025, 2:00pm

Video

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.